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Preface to the Seventh Edition
The mission of the ASBMR Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism is to present core knowledge in this field in a comprehensive yet concise fashion. In the two years since publication of the Sixth Edition, substantial new information has advanced our understanding of bone biology, mineral homeostasis, hormonal regulation, and the associated disease states. The Seventh Edition reflects these rapid and exciting advances in the basic sciences and translational research. Each of the major sections now includes an overview which provides the reader with an opportunity to understand the scope and implications of the chapters contained within it. Under the guidance of Jane Lian and Juliet Compston, we added several new chapters, and expanded the text by nearly one third. We increased our international representation on the editorial board and among authors. In the Seventh Edition, we added a new section on animal models that includes everything from mouse genetics to phenotyping and structural correlates. We expanded the section related to malignancy and bone under the guidance of Dr. Theresa Guise and included sections on the management of bone pain from cancer and the treatment of metastatic bone disease. Genetics is now covered more extensively, for mouse and humans, and methods for measuring bone mass have been expanded to keep pace with recent technology. Dr. Laurie McCauley spearheaded an expansion of the oral and maxillofacial section to include new concepts, and expand on a discussion of osteonecrosis of the jaw. The appendix is now much larger and includes not only reference data, but Web-based links to multiple sites for ease of use. This appendix will appear on the Primer wcbsite (www.asbmrprimer.org) and is free to access. In addition, Dr. Bouillon did an outstanding job updating approved drugs for metabolic bone diseases for both national and international members. In total, some chapters have been consolidated, others expanded, but all continue the role of the Primer as an essential resource for house staff, graduate students, fellows, and junior faculty. We believe the 7th edition will prove even more valuable for the many scientists, trainees, and physician practitioners who are intrigued and challenged by the complexities of the bone, its regulatory hormones, and the related diseases.
The Seventh Edition of the Primer is the first without Dr. Murray Favus as Editor in Chief. We continue to owe him a debt of gratitude for his previous successes in modeling the Primer as the most complete and up to date source of information in the field. This edition also represented a complete change in the editorial board, with two new associate editors, Jane Lian and Juliet Compston, as well as new assistant editors: Drs. Vicki Rosen, Socrates Papapoulos, Pierre Delmas, Raj Thakker, Paul Miller, Laurie McCauley, Richard Keene, Ego Seeman, Marie Demay, Roger Bouillon, Theresa Guise, and Suzanne Jan de Beur. As such, this edition is a remarkable accomplishment and a testimony to the hard work, collegiality, and fellowship of this editorial board. It is even more remarkable considering the increase in breadth and depth that was undertaken in this publication. Our initial goal was to expand the number of chapters by nearly one third, and enhance the appendix, both as a reference component and as a gateway for Web-based references.
The Seventh Edition of the Primer is the product of a tripartite collaboration involving an experienced editorial board, skilled authors and an enthusiastic and supportive ASBMR editorial staff. The ASBMR staff, seasoned by the initial experience of self-publication with the Fifth Edition, has improved the publication process in many ways that benefited the authors and editors. The JBMR staff under the leadership of Matt Kilby must also be credited with expanding the distribution of the Primer and delivering it into the hands of so many more students, trainees, scientists, and physician practitioners than we ever envisioned. Matt's tireless efforts on the part of the Primer are greatly appreciated.
The evolution of the Primer is an ongoing process, and just as we complete the Seventh Edition we look forward to continuing this work in the Eighth Edition.
Of course, it is the contributing authors who have made the Primer a valuable source of information in the bone field. The editorial board is deeply indebted to the many authors who over the years have articulated in print the state of their areas of expertise and to the new authors who have given so much of their valuable time to this endeavor. This impressive group has successfully taken on the challenge of organizing the ever-expanding scientific information into a coherent presentation.
Clifford J. Rosen, M. D. Maine Medical Center Research Institute Scarborough, Maine
The untimely death of Dr. Pierre Delmas, one of the associate editors of the Primer, is a tragic loss to the Society, to the editors of this book, and to all who work in the field of metabolic bone diseases. His commitment to research, teaching, and promoting public health will be valued for years to come. The Seventh Edition of the Primer is dedicated to his legacy.
Preface for Primer
The American Along with these changes, Dr. Roger Bouillon was tasked with creating an international appendix, which can be seen on the Primer Website (www.asbmrprimer.org). Among the tables is a formulary of drugs used in the treatment of bone disorders and their availability throughout the world. The appendix will be located online only to allow extra room for broad coverage of topics in the book, as well as to make this information freely accessible online.
The Seventh Edition of our Primer upholds the tradition of excellence set by its predecessors while carving its own niche into our science and our lives. We commend the efforts of everyone involved. 
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Skeletal Morphogenesis and Embryonic Development
Signal 
INTRODUCTION
Formation of the skeletal system is one of the hallmarks that distinguish vertebrate animals from invertebrate ones. In higher vertebrates (i.e., birds and mammals), the skeletal system contains mainly cartilage and bone that are mesodermderived tissues and formed by chondrocytes and osteoblasts, respectively, during embryogenesis. A common mesenchymal progenitor cell also referred as the osteochondral progenitor gives rise to both chondrocytes and osteoblasts. Skeletal development starts from mesenchymal condensation, during which mesenchymal progenitor cells aggregate at future skeletal locations. Because mesenchymal cells in different parts of the embryo come from different cell lineages, the locations of initial skeletal formation determine which of the three mesenchymal cell lineages contribute to the future skeleton. Neural crest cells from the branchial arches contribute to the craniofacial bone, the sclerotome compartment of the somites gives rise to most axial skeletons, and lateral plate mesoderm form the limb mesenchyme, from which limb skeletons are derived ( Fig. 1 ). Ossification is one of the most critical processes in bone development, and this process is controlled by two major mechanisms: intramembranous and endochondral ossification. Osteochondral progenitors differentiate into osteoblasts to form the membranous bone during intramembranous ossification, whereas during endochondral ossification, osteochondral progenitors differentiate into chondrocytes instead to form a cartilage template of the future bone. The location of each skeletal element also determines its ossification mechanism and unique anatomic properties such as the shape and size. Importantly, the positional identity of each skeletal element is acquired early in embryonic development even before mesenchymal condensation through a process called pattern formation.
Cell-cell communication that coordinates cell proliferation and differentiation plays a critical role in pattern formation. Patterning of the early skeletal system is controlled by several major signaling pathways that also regulate other pattern formation processes. These signaling pathways are mediated by Wnts, Hedgehogs (Hhs), Bone morphogenetic proteins (BMPs), fibroblast growth factors (FGFs), and Notch/Delta. Later in skeletal development in a different cell context, these signaling pathways also control cell fate determination, proliferation, and maturation in the skeleton.
EARLY SKELETAL PATTERNING
In the craniofacial region, neural crest cells are major sources of cells establishing the craniofacial skeleton.") It is the temporal-and spatial-dependent reciprocal signaling between and among the neural crest cells and the epithelial cells (surface ectoderm, neural ectoderm or endodermal cells) that ultimately establish the pattern of craniofacial skeleton formed by neural crest cells.(2) Patterning of the axial skeleton can be traced back to the formation of somites, which are segmented mesodermal structure on either side of the neural tube and the underlying notochord. Somites give rise to axial skeleton, stri-
The author states that she has no conflicts of interest. ated muscle, and dorsal d e r m i~. (~-~' The repetitive and leftright symmetrical patterning of axial skeleton is controlled by a molecular oscillator or the segmentation clock and gradients of signaling molecules that act in the presomitic mesoderm (PSM) ( Fig. 2A) . The segmentation clock is operated by cyclic expression of genes, most of which are components of the Notch and canonical Wnt signaling pathways ( Fig. 2B ). (7. x)
The Notch signaling pathway mediates short-range communication between contacting cells. The FGF and retinoic acid (RA) signaling also control somatogenesis by regulating the competence of PSM cells to undergo segmentation. They form two opposing and functionally antagonistic gradients within the PSM ( Fig. 2A ).(l2) R A signaling has an additional role in maintaining left-right bilateral symmetry of somites by interacting and coordinating with the signaling pathways establishing left-right asymmetry of the body axis and the segmentation clock of the so mite^.('^-'")
The functional significance of segmentation clock in human skeletal development is highlighted by congenital axial skeletal diseases. Abnormal vertebral segmentation (AVS) in humans is a relatively common malformation. For instance. mutations in the NOTCH signaling components cause at least two human disorders, spondylocostal dysostosis (SCD, 277300, 608681, and 609813) and Alagille syndrome (AGS, OMIM 118450 and 610205); both exhibit vertebral column defects.
The formed somite is also patterned along the dorsal-ventral axis by cell signaling from the surface ectoderm, neural tube and the notochord (Fig. 1) . Ventralizing signals such as Sonic hedgehog (Shh) from the notochord and ventral neural tube is required to induce sclerotome formation on the ventral whereas Wnt signaling from the surface ectoderm and dorsal neural tube is required for the formation of dermomyotome on the dorsal side of the somite (Fig. 1) . (19, 20) The sclerotome gives rise to the axial skeleton and the ribs. In the mouse mutant that lacks Shh function, vertebral column and posterior ribs failed to form. The paired domain transcription factor Pax1 is expressed in the sclerotome, and Shh is required to regulate its expression. (21 -23) However, axial skeletal phenotypes in PaxI mutant mice(24' were far less severe than those in the Shh mutants.
SKELETAL MORPHOGENESIS A N D EMBRYONIC DEVELOPMENT I 3
Limb skeletons are patterned along the proximal-distal (P-D, shoulder to digit tip), anterior-posterior (A-P, thumb to little finger), and dorsal-ventral (D-V, back of the hand to palm) axis ( Fig. 3 ). Along the P-D axis, the limb skeletons form three major segments: humerus or femur at the proximal end, radius and ulna or tibia and fibula in the middle, and carpal/ tarsal, metacarpalhetatarsal and digits in the distal end. Along the A-P axis, the radius and ulna have distinct morphological features; so does each of the five digits. Patterning along the D-V limb axis also results in characteristic skeletal shapes and structures. For instance, the sesamoid processes are located ventrally whereas the knee patella forms on the dorsal side of the knee. The 3D limb patterning events are regulated by three signaling centers in the early limb primordium called the limb bud before mesenchymal condensation.
The apical ectoderm ridge (AER), a thickened epithelial structure formed at the distal tip of the limb bud, is the signaling center that directs P-D limb outgrowth ( Fgf family members that are expressed in the AER, mainly Fgf8 and Fgf4, are necessary and sufficient to mediate the function of A E R . (~~-*~) F gf10 expressed in the presumptive limb mesoderm is required for limb initiation and it also controls limb outgrowth by maintaining Fgf8 expression in the
The second signaling center is the zone of polarizing activity (ZPA), which is a group of mesenchymal cells located at the posterior distal limb margin and immediately adjacent to the A E R (Fig. 3B ). When Z P A tissue is grafted to the anterior limb bud under the AER, it leads to digit duplication in mirror image of the endogenous ones. (32) Shh is expressed in the Z P A and is both necessary and sufficient to mediate ZPA activity in patterning digit identity along the A-P However, the A-P axis of the limb is established before Shh signaling. This pre-Shh A-P limb patterning is controlled by combined activities of Gli3, A1x4, and basic helix-loop-helix (bHLH) transcription factors dHand and Twistl. The Gli3 repressor form (GIi3R) and AIx4 establish the anterior limb territory by re- The third signaling center is the non-AER limb ectoderm that covers the limb bud. It sets up the D-V polarity of not only the ectoderm but also the underlying mesoderm of the limb (Fig. 3C ).(3y,4") Wnt and BMP signaling are required to control D-V limb polarity of both the limb ectoderm and mesoderm. Wnt7u is expressed specifically in the dorsal limb ectoderm, and it activates the expression of Lmxlb, which encodes a dorsal-specific LIM homeobox transcription factor that determines the dorsal id en tit^.(^',^*) Wnt7u expression in the ventral ectoderm is suppressed by En-1, which encodes a transcription factor that is expressed specifically in the ventral e~t o d e r m . (~~) The BMP signaling pathway is also ventralizing in the early limb (Fig. 3C ). The function of BMP signaling in the early limb ectoderm is upstream of En-f in controlling D-V limb polar-it^.'^^' However, in the mouse limb bud mesoderm, BMPs also have En-I-independent ventralization activity by inhibiting Lmxlb expression. (45) Limb development is a coordinated 3D event. Indeed, the three signaling centers interact with each other through interactions of the mediating signaling molecules. First, there is a positive feedback loop between Shh and Fgfs expressed in the AER, which connects A-P limb patterning with P-D limb outgrowth ( Fig. 3B ).(4h-4H) Second, the dorsalizing signal Wnt7a is required for maintaining the expression of Shh that patterns the A-P
EMBRYONIC CARTILAGE AND BONE FORMATION
The early patterning events determine where and when the mesenchymal cells condense. After that, osteochondral progenitors in the condensation form either chondrocytes or osteoblasts. Sox9 and Runx2, master transcription factors that are required for the determination of chondrocyte and osteoblast cell fates, r e s p e~t i v e l y , (~' -~~) are both expressed in osteochondral progenitor cells, but SoxY expression precedes that of Runx2 in the mesenchymal condensation in the limb.(") Early SoxY-expressing cells give rise to both chondrocytes and osteoblasts regardless of ossification mechanisms.'56) In addition, loss of SoxY function in the limb leads to loss of mesenchymal condensation and Runx2 expression.'") Coexpression of Sox9 and Runx2 is terminated on chondrocyte and osteoblast differentiation. SoxY and Runx2 expression are quickly segregated into chondrocytes and osteoblasts, respectively. Understanding the mechanism controlling this expression segregation of SoxY and Runx2 in specific cell lineages is fundamental to elucidate the regulation of not only chondrocyte and osteoblast differentiation but also the determination of ossification mechanism. It is clear that cell-cell signaling, particularly those mediated by Wnts and Indian hedgehog (Ihh), are required for cell fate determination of chondrocytes and osteoblasts by controlling the expression of Sox9 and Runx2.
Active canonical Wnt signaling is detected in the developing calvarium and perichondrium where osteoblasts differentiate through either intramembranous or endochondral ossification. Indeed, enhanced canonical Wnt signaling enhanced bone formation and Runx2 expression, but inhibited chondrocyte differentiation and SoxY e~pression.("~~") Conversely, removal of p-cutenin in osteochondral progenitor cells resulted in ectopic chondrocyte differentiation at the expense of osteoblasts during both intramembranous and endochondral ossification.('"-'') Therefore, the mesenchymal progenitor cells in the condensation are at least bipotential in their final cell fate determination. During intramembranous ossification, Wnt signaling in the condensation is higher, which promotes osteoblast differentiation while inhibiting chondrocyte differentiation. During endochondral ossification, however, Wnt signaling in the condensation is kept low such that only chondrocytes can differentiate. Later, when Wnt signaling is upregulated in the periphery of the cartilage, osteoblasts will differentiate. Thus, by manipulating Wnt signaling, mesenchymal progenitor cells, and perhaps even mesenchymal stem cells, can be directed to form only chondrocytes, which is needed in repairing cartilage damage in osteoarthritis, or only form osteoblasts, which will lead to new therapeutic strategies to treat osteoporosis. These studies also provide new insights to tissue engineering that aims to fabricate cartilage or bone in vitro using mesenchymal progenitor cells or stem cells.
Ihh signaling is required for osteoblast differentiation by activating Runx2 expression only during endochondral bone formation.("','" Ihh is expressed in newly differentiated chondrocytes, and Ihh signaling does not seem to affect chondrocyte differentiation from mesenchymal progenitors. However, when Hh signaling is inactivated in the perichondrium cells, they ectopically form chondrocytes and express SoxY at the expense of Runx2. This is similar to what has been observed in the Osterix ( O n ) mutant embryos, except that, in the OW'embryos, ectopic chondrocytes express both SoxY The sequential actions of Hh and Wnt signaling in osteoblast differentiation and maturation suggest that Hh and Wnt signaling need to be manipulated at distinct stages during fracture repair and tissue engineering.
The BMP family of secreted growth factors belong to the T G F superfamily. BMPs were identified as secreted proteins that have the ability to promote ectopic cartilage and bone f~r r n a t i o n . '~~' Unlike Ihh and Wnt signaling, BMP signaling promotes the differentiation of both osteoblast and chondrocyte differentiation from mesenchymal progenitors. The mechanisms underlying these unique activities of BMPs have been under intense investigation in the last two decades. During the course, understanding BMP action in chondrogenesis and osteogenesis has benefited greatly from molecular studies of BMP signal transduction.'hx) Reducing BMP signaling by removing BMP receptors leads to impaired chondrocyte and osteoblast differentiation and maturation.('") F G F ligands and F G F receptors (FGFRs) are both expressed in the developing skeletal system, and the significant role of FGF signaling in skeletal development was first identified by the discovery that achondroplasia (ACH; OMIM lOOSOO), the most common form of skeletal dwarfism in humans, was caused by a missense mutation in FGFR3. Later, hypochondroplasia (HCH; OMIM 146000), a milder form of dwarfism, and thanatophoric dysplasia (TD; OMIM 187600 and 187601), a more severe form of dwarfism, were also found to result from mutations in FGFR3. FGFR3 signaling acts to regulate the proliferation and hypertrophy of the differentiated chondrocytes. However, the function of F G F signaling in 
CHONDROCYTE PROLIFERATION AND DIFFERENTIATION IN THE DEVELOPING CARTILAGE
During endochondral bone formation, chondrocytes differentiated from the mesenchymal condensation form the cartilage, which provides a growth template for the future bone. Differentiated chondrocytes inside the cartilage undergo tightly controlled progressive proliferation and hypertrophy, which is required for endochondral bone formation. In the developing cartilage of the long bone, chondrocytes with different properties of proliferation and differentiation are located in distinct zones along the longitudinal axis, and such organization is required for long bone elongation (Fig. 4A) . Proliferating chondrocytes express Coll, whereas hypertrophic chondrocytes express ColX. The chondrocytes that already exit cell cycle, but have not yet become hypertrophic, are prehypertrophic chondrocytes. These cells and early hypertrophic chondrocytes express Ihh, which is a master regulator of endochondral bone development by coupling chondrocyte hy-6 / CHAPTEK 1 pertrophy with osteoblast differentiation as Ihh is produced by prehypertrophic chondrocytes and signals to the adjacent perichondrium to induce osteoblast differentiation.'") 1hh-I-mice have striking skeletal development defects. Apart from lack of endochondral bone formation, all cartilage elements are small because of a marked decrease in chondrocyte proliferation.(hs~7") Ihh also controls the pace of chondrocyte hypertrophy by activating the expression of PTH-related peptide (PTHrP) in articular cartilage and periarticular ~e l l s . (~~.~' ) PTHrP acts on the same G protein-coupled receptor used by PTH. This PTH/PTHrP receptor (PPR) is expressed at much higher levels by prehypertrophic and early hypertrophic chondrocytes. PTHrP signaling is required to inhibit precocious chondrocyte hypertrophy primarily by keeping proliferating chondrocytes in the proliferating pool. (72.73) PTHrP signaling is also required to mediate the activity of Ihh in regulating chondrocyte hypertrophy but not proliferat i~n . (~~) Therefore, Ihh and PTHrP form a negative feedback loop to control the decision of chondrocytes to leave the proliferating pool and become hypertrophy (Fig. 4B ). In this model, PTHrP, secreted from cells at the ends of cartilage, acts on proliferating chondrocytes to keep them proliferating. When chondrocytes are further away from the end of cartilage as a result of cartilage elongation, they are no longer sufficiently stimulated by PTHrP. These cells exit cell cycle and become Ihh-producing prehypertrophic chondrocytes. Ihh stimulates P T H r P expression at the ends of cartilage to slow down cell cycle exit of proliferating chondrocytes. This model is sup orted by experiments using chimeric mouse embryos.'T1-5) Clones of PPR-'chondrocytes differentiate into hypertrophic chondrocytes and produce Ihh within the wildtype proliferating chondrocyte domain. This ectopic Zhh expression leads to ectopic osteoblast differentiation in the perichondrium, an upregulation of P T H r P expression, and a consequent lengthening of the columns of wildtype proliferating chondrocytes. These studies show that the lengths of proliferating columns, hence the growth potential of cartilages, are critically determined by the Ihh-PTHrP negative feedback loop. Indeed, it has been found that mutations in IHH in humans cause brachydactyly type A 1 (OMIM 112500), which exhibit shortened digits phalanges and short body statue.(7h) This feedback loop may also act to assure that cells at the hypertrophic front exit cell cycle and undergo hypertrophy at the same time.('" Several Wnt ligands including WntSa, WntSb, Wnt4, and Wnt9a are expressed in the cartilage and perichondrium of mouse embryo^.('^,^^) Wnt4 and Wnt9a signal through the canonical Wnt pathway, whereas Wnt5a and Wnt5b signal through the P-catenin-independent (noncanonical) pathways to regulate chondrocyte proliferation and hypertrophy. Although the mechanisms vary, in the absence of either canonical or noncanonical Wnt signaling, chondrocyte proliferation is altered, and chondrocyte hypertrophy is delayed.("".77*7x) Fu rthermore, both the canonical and noncanonical Wnt pathways act in parallel with Ihh signaling to regulate chondrocyte proliferation and Wnt and Ihh signaling may both re ulate common downstream targets such as Sox9 (see be lo^)?^^.^' ) Many F G F ligands and receptors are expressed in the developing cartilage. The likely functional redundancy of the FGF ligand and receptor members in cartilage development is a challenging issue that needs to be addressed to cleanly dissect the function of FGF signaling. FGFR3 signaling negative1 regulates chondrocyte proliferation and hypertrophy.(7"xh4; Furthermore, FGFR3 signaling does so in part by directly signaling in c h o n d r o~y t e s (~~~~" ) to activate the Janus kinase signal transducer and activator of transcription-1 (Jak-Statl) and the MAPK pathways.(") FGFR3 signaling also interacts with the IhhiPTHrPIBMP signaling pathways.(x'.yo~y'" The proliferation-inhibitory role of Fgf signaling in chondrocytes is not unique to FGFR3. When expressed in growth plate chondrocytes in vivo, both FGFRl and FGFR3 kinase domains seem to have similar activities.'"')
Because Fgf18-'-mice show an increase in chondrocyte proliferation that closely resembles the cartilage phenotypes of Fgfr3-'-mice, FGF18 is likely a physiological ligand for FGFR3 during skeletal development. However, the phenotype of the Fgfl8-'-mouse is more severe than that of the Fgfr3-'mice, suggesting that Fgf18 may also signal through Fgfrl in hypertrophic chondrocytes and Fgfr2 and -1 in the perichondrium. Mice conditionally lacking Fgfr2 develop skeletal dwarfism with decreased BMD.(y3,y4) Osteoblasts also express Fgfr3, and mice lacking Fgfr3 have decreased BMD and develop ~steopenia.('~.'~) Thus, in osteoblasts, F G F signaling positively regulates bone growth by promoting osteoblast proliferation. Interestingly, mice lacking Fgfz also show osteopenia, although much later in development than in Fgfr2deficient mice,("7) suggesting that F G M may be a homeostatic factor that replaces the developmental growth factor, FGF18, in adult bones. It is still not clear which FGFR (1, 2, or 3) is actually responding to FGF2/18 in osteoblasts.
Like the other major signaling pathways mentioned above, BMP signaling also acts during later stages of cartilage development. Both in vitro limb explant experiments and in vivo genetic studies showed that BMP signaling promotes chondrocyte proliferation and Ihh expression. Addition of BMPs to bone explants increases proliferation of chondrocytes, whereas Noggin blocks chondrocyte proliferation.(".'") In addition, conditional removal of both BmpRIA and BmpRIB in differentiated chondrocytes leads to reduced chondrocyte proliferation and Ihh expression. BMP signaling also regulates chondrocyte hypertrophy because removal of B m p R l A in chondrocytes leads to an expanded hypertrophic zone caused by accelerated chondrocyte hypertrophy and delayed terminal maturation of hypertrophic chondrocytes.('') Given the function of Ihh in promoting chondrocyte proliferation and controlling the pace of chondrocyte hypertrophy, BMP signaling regulates chondrocyte proliferation and hypertrophy at least in part through Ihh expression.
BMP signaling also interacts with FGF signaling through mutual antagonism. In limb explant cultures, BMP and FGF signalin pathways have opposing functions in the growth BMP and FGF signaling mutants indicate that these two signaling pathways antagonize each other in regulating chondrocyte proliferation and hypertrophy.('9) The molecular mechanisms of BMP/FGF antagonism requires further study.
Chondrocytes in the developing cartilage transduce distinct signals including Ihh, PTHrP, Wnts, FGFs, and BMPs at the same time. A complete understanding of the molecular regulation of cartilage development will not be achieved without deciphering how these signaling pathways interact with each other and coordinately control common downstream effectors inside the cell. sox9 and Runx2 are two critical transcription factors that can integrate various signaling inputs in controlling chondrocyte proliferation and differentiation. When Sox9 was removed from differentiated chondrocytes, chondrocyte proliferation, expression of matrix genes, and the Ihh-PTHrP signaling components were reduced in the cartilage.(5s' These phenotypes are very similar to those mutant mice lacking both Sox5 and Soxb, two other Sox-family members that themselves require Sox9 for expression. sox5 and Sox6 cooperate with Sox9 in maintaining chondrocyte phenotypes and regulating chondrocyte specific gene expression.'"")) Haploinsufficiency Thus, sox9 is a master transcription factor that act in many critical stages of chondrocyte proliferation and differentiation as a central node inside pre-chondrocytes and chondrocytes to receive and integrate multiple signaling inputs.
Runx2 is expressed in prehypertrophic and hypertrophic chondrocytes. It is also highly expressed in perichondrial cells and in osteoblasts. The significant role of Runx2 in skeletal development is first shown by the striking phenotypes of Runx2-/-mice. These mutant mice have no osteoblast differentiation at a11.(52~1"') Mutations in human RCJNX2 cause cleidocranial dysplasia (CCD; OMIM 119600), an autosomaldominant condition characterized by hypoplasia/aplasia of clavicles, patent fontanelles, supernumerary teeth, short stature, and other changes in skeletal patterning and growth.('"4) Runx2 is the earliest known transcription factor that is required for osteoblast differentiation from mesenchymal progenitors. Runx2 also controls chondrocyte proliferation and hypertrophy. Chondrocyte hypertrophy is significantly delayed, and Zhh expression is reduced in Runx2-'-mice, whereas Runx2 overexpression in the cartilage results in accelerated chondrocyte hypertrophy.('05~'06) Furthermore, removing both R u m 2 and Runx3 completely blocks chondrocyte hypertrophy and Zhh expression in mice, indicating Runx transcription factors control Zhh expression.("") Thus, Runx2 can also be viewed as a master controlling transcription factor and a central node through which other signaling pathways are integrated in coordinate chondrocyte proliferation and hypertrophy. In chondrocytes, R u n d .acts in the Ihh-PTHrP pathway to regulate cartilage growth by controlling the expression of Zhh. However, this will not be its only function because Runx2 upregulation leads to accelerated chondrocyte hypertrophy, whereas Zhh upregulation leads to delayed chondrocyte hypertrophy. One of Runx2's Zhh-independent activities is to act in the perichondrium to inhibit chondrocyte proliferation and hypertrophy indirectly by regulating FgfZS expression.("'*) Interestingly, this role of Runx2 in the perichondrium is antagonist to its role in chondrocytes. Furthermore, histone deacetylases 4 (HDAC4), which modulates cell growth and differentiation by governing chromatin structure and repressing the activity of specific transcription factors, regulates chondrocyte hypertrophy and endochondral bone formation by interacting with and inhibiting the activity of R~nx2.""~)
REGULATION OF CHONDROCYTE SURVIVAL
Cartilage is an avascular tissue that develops under a hypoxia condition because chondrocytes, particularly the ones in the middle of the cartilage, d o not have access to vascular oxygen delivery.("') As in other hypoxia conditions, a major mediator of hypoxic response in the developing cartilage is the transcription factor hypoxia-inducible factor 1 (Hif-1) and its oxygen-sensitive component Hif-la. Removal of Hif-la in cartilage results in chondrocyte cell death in the interior of the growth plate. A downstream target of Hif-1 in regulating chondrocyte hypoxic response is Vegf.(' ") The extensive cell death seen in the cartilage of mice lacking Vegfa has a striking similarity to that observed in mice in which Hif-la is removed in the developing cartilage. In addition, Vegf expression in the growth plate is reduced in the absence of Hif-Za.(' I") However, Vegf expression is also regulated through Hif-la-independent mechanisms, possibly as a result of alternative response to hypoxia in the Hif-la cartilage-specific mutant. In this mutant, upregulation of Vegf expression and ectopic angiogenesis are observed in chondrocytes surrounding areas of extensive cell death.(' '(I)
CONCLUSIONS
Being able to use autologous cells and tissues to repair damaged bone and cartilage during injury and diseases has obvious advantages and will be a big step forward in regenerative medicine. With the possibility of reprogramming somatic cells into embryonic stem cells (ESCs), one may be able to fabricate cartilage or bone using one's own reprogrammed ESCs. Because bone formation is a process that has been perfected by nature in embryos during vertebrate evolution, understanding the underlying molecular mechanism of cartilage and bone formation in embryonic development will allow us to learn the strategy in achieving directed differentiation of chondrocytes and osteoblasts from ESCs. In addition, such knowledge will significantly promote consistent cartilage or bone repair in vivo or grow functional cartilage or bone in vitro. Other transcription factors that are involved in osteoblast differentiation are homeobox proteins such as Msx2, Dlx-3, Dlx-5, Dlx-6, and members of the activator protein 1 (AP-I) family such as Fos, Fra, and ATF4. However, deficiency of these genes does not result in complete loss of osteoblasts like in Runx2-/mice and Osx-/-mice, pointing at a facilitory role in osteoblastogenesis.
INTRODUCTION
BMP SIGNALING
BMPs belong to the TGF-P superfamily and were originally identified as the active components in bone extracts capable of inducing bone formation at ectopic sites.('3) BMPs are expressed in skeletal tissue and are required for skeletal development and maintenance of adult bone homeostasis and play an important role in fracture healing.('4.'5' Conditional knockout mice deficient in BMP ligands or Smad proteins, the intracellular mediators of BMP signaling, in bone display skeletal
In addition, several naturally occurring mutations in BMPs or their receptors cause inherited disorders, including fibrodysplasia ossificans progressiva (FOP), (15,1h) in which bone is progressively formed at ectopic sites. Thus, the BMP signaling pathway fulfills a key role in skeletal development and bone remodeling.
BMPs bind as dimers to type 1 and type I1 serinekhreonine receptor kinases, forming an oligomeric complex (Fig. 2) . On oligomerization, the constitutively active type I1 receptors phosphorylate and consequently activate the type I receptors. Subsequently, the activated type I receptors phosphorylate BMP receptor-regulated Smads, Smadl, -5, and -8, at their extreme C termini. The receptor-regulated Smads associate with the Co-Smad, Smad4, and translocate into the nucleus, where they together with other transcription factors bind promoters of target genes and control their expression ( In addition, BMPs control expression of Id (inhibitor of differentiation or inhibitor of D N A binding) pro-tein~.(~'.'~) Id proteins are inhibitors of basic helix-loop-helix proteins that inhibit osteoblast differentiation. Indeed, BMPinduced bone formation in vivo was found to be suppressed in Idl/Id3 heterozygous knockout mice.(") Furthermore, BMP2 was found to induce expression of Osterix, which besides Runx2 also seems to be mediated by the p38 and c-Jun Nterminal kinase (JNK) MAP kinase ( Fig. 3 ).(' '. 26.27) 
TGF-P SIGNALING
TGF-P is implicated in the control of proliferation, migration, differentiation, and survival of many different cell types. TGF-P is one of the most abundant cytokines in bone matrix and plays a major role in development and maintenance of the skeleton, affecting both cartilage and bone metabolism. (28) Interestingly, TGF-P can have both positive and negative effects on bone formation depending on the context and concentration.
TGF-P signals through a similar mechanism as the related BMPs. However, on binding to its s ecific receptors, TGF-P induces activation of Smad2 and -3.877,'x) Smad3 overexpression in mouse osteoblastic MC3T3-El cells enhanced the levels of bone matrix proteins, ALP activity, and mineralization.(") As is the case for Smadl and -5. Runx2 also interacts with
